the Clinical Trial of Teicoplanin for Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Primary study endpoint Security Effectiveness
2. Secondary study endpoint Extensive use of population characteristics Clinical drug characteristics appropriate crowd characteristics Adverse reactions susceptible population characteristics Reveal rare, new, unanticipated and long-term adverse drug reactions bacterial resistance Explore the advantages of teicoplanin in combination with other antimicrobial agents Explore the opportunistic use of teicoplanin for injection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

NCT00079989

Gram-Negative Bacterial Infections

COMPLETED PHASE3

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

NCT06522945

Multi-resistant Gram-negative Bacteria Cause Infection

COMPLETED PHASE1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

NCT04482569

Bacterial Infections

COMPLETED PHASE1

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

NCT06394518

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Prosthetic Joints Infection (PJI)

COMPLETED PHASE1

Doripenem in the Treatment of Hospital-Acquired Pneumonia

NCT00211003

Pneumonia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research purposes

1. To explore the safety and efficacy of different doses of teicoplanin for injection in the real world
2. To explore the characteristics of different doses of teicoplanin for injection, the clinical characteristics of drug use and repeated use of bacterial resistance;
3. Reveal rare or even very rare, new, unanticipated, and adverse drug reactions associated with long-term use;
4. To explore the advantages of different doses of teicoplanin in combination with other antimicrobial agents;
5. To explore the use of teicoplanin in the treatment of infectious diseases on the rational use of drugs time;
6. To reveal the risk factors of adverse reactions and susceptibility to people, to identify the characteristics of the crowd;
7. To investigate the clinical use of teicoplanin injection for the real situation, for further risk management, to expand the indications and expert consensus dose study to provide clinical clues and basis;
8. To provide reference for revision of clinical guidelines and consensus, clinical pathway design;
9. To further enhance the level of safe use of teicoplanin injection, basic medical support and market vitality.

Research design

1. National, large-scale, standardized, standardized, real-world research;
2. Prospective, single - arm open, non - interventional, registration, multi - center clinical study;
3. In the hospitals using teicoplanin for injection, 200 were selected on the basis of voluntary principles;
4. Registration of teicoplanin in patients with injection;
5. Target sample size of 100,000 cases;
6. Exemption from informed consent for ethical review applications;
7. Study of teicoplanin and large-scale data on the safety and effectiveness of antibiotics.